Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB +28.00% Cash-to-Debt is 0.09 as of Jun. 2026, which is 72% below its 10-year median of 0.32. The stock has 8 warning signs investors should review. Among 842 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 91.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CurveBeam AI's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.09.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, CurveBeam AIcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for CurveBeam AI's Cash-to-Debt or its related term are showing as below:
ASX:CVB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 0.32 Max: 0.41
Current: 0.09
During the past 5 years, CurveBeam AI's highest Cash to Debt Ratio was 0.41. The lowest was 0.09. And the median was 0.32.
ASX:CVB's Cash-to-Debt is ranked worse than 91.57% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ASX:CVB: 0.09
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
CurveBeam AI Cash-to-Debt Related Terms
CurveBeam AI Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, CurveBeam AI's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a Cash-to-Debt of 0.09 as of Jun. 2026. This is 72% below median its historical median of 0.32. Over the past decade, CurveBeam AI's Cash-to-Debt has ranged from 0.09 to 0.41. According to the industry distribution chart, CurveBeam AI ranks #771 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 91.6%.
Is CurveBeam AI's Cash-to-Debt too high?
CurveBeam AI's current Cash-to-Debt of 0.09 is 72% below median its 10-year median of 0.32. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.41. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. CurveBeam AI's value of 0.09 is 94.5% below this industry median. Based on the distribution chart, CurveBeam AI ranks #771 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #771 out of 842 companies for Cash-to-Debt. This places CurveBeam AI in the lower half of its industry. The industry median Cash-to-Debt is 1.64. CurveBeam AI's value of 0.09 is 94.5% below this benchmark. Historically, CurveBeam AI's own Cash-to-Debt has ranged from 0.09 to 0.41 over the past decade. While the company's 10-year median is 0.32 vs. the industry median of 1.64, CurveBeam AI has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current Cash-to-Debt of 0.09 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Cash-to-Debt is 0.09, which is 72% below median its own 10-year median of 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
Based on GuruFocus' analysis, CurveBeam AI (ASX:CVB) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.06, compared to a current price of A$0.03 — trading 46.7% below its estimated fair value. The current Cash-to-Debt is 0.09, which is 72% below median its 10-year median of 0.32 and 94.5% below the Medical Devices & Instruments industry median of 1.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Cash-to-Debt is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
